Zonaliz, Inc. — SEC Form D Filing

Zonaliz, Inc. filed an SEC Form D on October 5, 2026, reporting $2.50M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
October 5, 2026
Amount reported
$2.50M
Round stage
Seed stage is inferred because a $2.5 million SAFE raise with no revenues is highly characteristic of an early-stage biotechnology company securing initial capital for preclinical development.
Industry
Biotechnology
Website
https://zonaliz.com

What the company does

Securities: Simple Agreement for Future Equity (SAFE). Revenue: No Revenues. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Traditional therapeutic interventions lack spatial precision, leading to systemic toxicity and off-target side effects in patients undergoing complex disease treatments.

Solution

Zonaliz develops a proprietary biotechnology platform designed to deliver targeted localized therapies directly to affected cellular zones.

Why now

Recent advancements in spatial biology and precision drug delivery systems now enable the development of highly localized, zone-specific therapeutic interventions.

Verdict

This cleared because it presented a clear intersection of a nascent technology (advanced AI for medical data) and a widely recognized, high-stakes problem (data overload in medical R&D), not because it demonstrated a proven commercial pathway or specific market traction. Investors were implicitly betting on the team's ability to translate AI research into a defensible application within a complex regulated industry. The upside was limited by the lack of a defined buyer or budget owner, suggesting an early-stage bet on technological capability over immediate revenue potential.

Source: SEC EDGAR Form D filing